Easy To Use Human Fgfr2 Alpha (iiib) Protein (fgr-hm1bd) - Today Only [34KVDfqI]

Human FGFR2 alpha (IIIb) Protein

Welcome to our Easy To Use Human Fgfr2 Alpha (iiib) Protein (fgr-hm1bd) - Today Only [34KVDfqI], a high-quality recombinant protein derived from human cells. This protein is meticulously engineered to provide researchers with a reliable and consistent source for their experiments. With its exceptional purity and stability, the Human FGFR2 alpha (IIIb) Protein is ideal for a wide range of applications, including cell culture, western blotting, and protein-protein interaction studies.

• Purity: Our protein is >95% pure, ensuring accurate and reliable results.
• Stability: The protein is stable at 2-8°C for at least 12 months, providing long-term storage convenience.

Key Features and Specifications

The Easy To Use Human Fgfr2 Alpha (iiib) Protein (fgr-hm1bd) - Today Only [34KVDfqI] is a recombinant protein produced in E. coli, which offers several key advantages. This protein is expressed as an N-terminally His-tagged fusion protein, making it easier to purify and work with. It is also designed to be biologically active, ensuring that your experiments yield accurate and reproducible results.

• Expression System: E. coli expression system for high yield and ease of purification.
• Activity: Biologically active, ready for use in various experimental applications.

Practical Uses and Benefits

Whether you are conducting research in oncology, developmental biology, or any other field involving FGFR2 signaling, the Easy To Use Human Fgfr2 Alpha (iiib) Protein (fgr-hm1bd) - Today Only [34KVDfqI] is an invaluable tool. This protein can be used to study the role of FGFR2 in various cellular processes, such as cell proliferation, differentiation, and apoptosis. By using our protein, you can gain a deeper understanding of FGFR2's mechanisms and potential therapeutic targets.

• Research Applications: Ideal for cell culture, western blotting, and protein-protein interaction studies.
• Therapeutic Potential: Contribute to the development of new treatments for diseases associated with FGFR2 dysregulation.